세계의 테스토스테론 보충 요법 시장 : 기회, 성장 촉진요인, 산업 동향 분석, 예측(2025-2034년)

The Global Testosterone Replacement Therapy Market reached USD 1.9 billion in 2024 and is set to expand at a CAGR of 4.2% between 2025 and 2034. This growth is fueled by the rising incidences of hypogonadism and increased awareness about its diagnosis and treatment options. As more men seek solutions for testosterone deficiency, advancements in therapeutic approaches and growing acceptance of hormone replacement therapies are driving demand.

A surge in awareness campaigns, improved healthcare infrastructure, and patient-focused drug delivery systems have made testosterone replacement therapy more accessible. The shift toward personalized medicine and innovations in treatment formulations are further accelerating market momentum. These developments ensure that the testosterone replacement therapy market remains a key focus in addressing the needs of patients suffering from hormonal deficiencies.

In 2024, injectables dominated the market, generating USD 1.1 billion in revenue. These products outperform gels and patches due to their ability to provide stable and predictable testosterone levels. With reliable bioavailability, ease of dosage adjustment, and the capability to tailor treatment plans, injectables have become the preferred choice for both patients and healthcare providers. These benefits contribute to better patient outcomes, securing injectables' leadership position in the testosterone replacement therapy market.

Among active ingredients, testosterone cypionate led the segment, accounting for USD 636.1 million in revenue in 2024, and anticipated to grow at a CAGR of 4.5% through 2034. Known for its extended duration of action, testosterone cypionate typically requires injections only once every one to two weeks, significantly reducing the frequency of administration. This convenience improves patient adherence and has established the compound as a go-to option for healthcare providers seeking effective and manageable treatment solutions.

The U.S. testosterone replacement therapy market reached USD 736.1 million in revenue in 2024, with a projected CAGR of 3.5% over the forecast period. The market's growth is supported by a well-established healthcare infrastructure, the presence of leading pharmaceutical manufacturers, and favorable reimbursement policies. Innovations in delivery methods, such as gels, patches, and injections, have increased accessibility and patient acceptance. Rising demand for these advanced therapies underscores the country's dominant position in the global testosterone replacement therapy market.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of hypogonadism
    • 3.2.1.2 Advancements in drug delivery
    • 3.2.1.3 Growing awareness about hypogonadism
    • 3.2.1.4 Expanding aging population
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Side effects and risks
• 3.3 Growth potential analysis
• 3.4 Pricing analysis, 2024
• 3.5 Regulatory landscape
• 3.6 Reimbursement scenario
• 3.7 Technology landscape
• 3.8 Pipeline analysis
• 3.9 Porter’s analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Injectables
• 5.3 Topicals
• 5.4 Other product types

Chapter 6 Market Estimates and Forecast, By Active Ingredients, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Testosterone cypionate
• 6.3 Testosterone
• 6.4 Testosterone enanthate
• 6.5 Testosterone undecanoate
• 6.6 Other active ingredients

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Brick & mortar
• 7.3 E-commerce

Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 AbbVie
• 9.2 Antares Pharma
• 9.3 Cipla
• 9.4 Eli Lilly & Co.
• 9.5 Endo International
• 9.6 Ferring Pharmaceuticals
• 9.7 Halozyme
• 9.8 Lupin
• 9.9 Marius Pharmaceuticals
• 9.10 Pfizer
• 9.11 Sun Pharmaceutical Industries
• 9.12 Teva Pharmaceuticals
• 9.13 Tolmar